04Sep
12Aug
Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research
Silo Pharma, Inc., a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control. Read more >>
21Jul
Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, has been awarded a $1,700,000 Small Business Innovation Research (SBIR) grant to advance Zylö’s proprietary nitric-oxide-releasing topical drug candidate into clinical trials. Read more >>
20May
Zylö and Amifar Laboratorios Forge Broad-Ranging Partnership
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into a broad-ranging agreement with Amifar Laboratorios Spain to supply Z-pods to further enhance Amifar’s new line of advanced cosmetics. Amifar and Zylö have initiated a product development collaboration beginning with two actives and have plans to expand the list of actives over time. Read more >>
22Dec
Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model
Hoth has a partnership agreement with Zylö Therapeutics Inc., to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Read more >>
04Nov
Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
Hoth Therapeutics, Inc., a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease. The study conducted by Jackson Laboratory in partnership with Zylö Therapeutics using a CLE mouse model demonstrated a significant reduction in skin plaque severity after treatment with HT-005-loaded topical Z-pods™ compared to untreated control mice. Read more >>
02Sep
Jay Blankenship M.D. Joins Zylö as Vice President of Business Development
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced Jay Blankenship M.D. has joined its executive team as vice president of business development. Read more >>
26Aug
Grapefruit USA, Inc. Commences Production of Its Patented Disruptive Time Release Hourglass(TM) THC+CBD Delivery Cream
Grapefruit USA, Inc., a fully licensed California based cannabis company, is announcing today that it has commenced production of the Hourglass™ time release THC+CBD delivery cream at its manufacturing facility in the Coachillin Canna-Business Park in Desert Hot Springs, California, pursuant to its Exclusive License and Supply Agreement with Zylö Therapeutics Inc. Read more >>
29Jul
Zylö and Grapefruit Forge Partnership That Promises to Disrupt the Topical Cannabis Market
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into an exclusive agreement with Grapefruit USA, Inc. to supply its Z-pod™ system as the technological underpinning of Grapefruit’s Hourglass™ time-release cannabinoid topical cream. Read more >>
04Jun